Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 4/20 | 0.47 |
| ▸ | HTR2A | P28223 | 2/20 | 0.47 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 6/20 | 0.45 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.45 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.45 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.45 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.45 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.45 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL708293 | 1.00 | DRD2 (0.47) | DRD2HTR2AMCHR1CHRM1CHRM5 | |
| SCHEMBL707602 | 0.86 | KCNH2 (0.51) | MCHR1CHRM1CHRM5CHRM3KCNH2 | |
| SCHEMBL707601 | 0.86 | KCNH2 (0.51) | MCHR1CHRM1CHRM5CHRM3KCNH2 | |
| SCHEMBL704735 | 0.83 | KCNH2 (0.42) | CHRM1CHRM5CHRM3PIK3CDPIK3CA | |
| SCHEMBL711421 | 0.83 | KCNH2 (0.42) | CHRM1CHRM5CHRM3PIK3CDPIK3CA | |
| SCHEMBL711420 | 0.83 | KCNH2 (0.42) | CHRM1CHRM5CHRM3PIK3CDPIK3CA | |
| SCHEMBL30665902 | 0.80 | DRD2 (0.58) | DRD2HTR2AMCHR1CHRM1CHRM5 | |
| SCHEMBL706080 | 0.76 | DRD2 (0.53) | DRD2HTR2AMCHR1CHRM1CHRM5 | |
| SCHEMBL707478 | 0.74 | CHRM1 (0.39) | DRD2HTR2AMCHR1CHRM1CHRM5 | |
| SCHEMBL707477 | 0.74 | CHRM1 (0.39) | DRD2HTR2AMCHR1CHRM1CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2289890-A1 | Compounds for the treatment of multi-drug resistant bacterial infections | AstraZeneca AB (SE) | 2011-03-02 | — | — | EP | claimed |
| US-20120108577-A1 | COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS | ASTRAZENECA AB (SE) | 2012-05-03 | — | — | US | disclosed |
| US-8124602-B2 | Compounds for the treatment of multi-drug resistant bacterial infections | ASTRAZENECA AB (SE) | 2012-02-28 | — | — | US | disclosed |
| US-20110092495-A1 | COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS | ASTRAZENECA AB (SE) | 2011-04-21 | — | — | US | disclosed |
| EP-2289890-A1 | Compounds for the treatment of multi-drug resistant bacterial infections | AstraZeneca AB (SE) | 2011-03-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092495-A1 | COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS | PIGS, BPGM, IPMK | DRD2 3243/4885HTR2A 4860/4885MCHR1 4238/4885 |
| US-20120108577-A1 | COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS | PIGS, BPGM, IPMK | DRD2 3243/4885HTR2A 4860/4885MCHR1 4238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.